Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer

Pectasides, D.; Visvikis, Anastasios; Kouloubinis, Alexandros; Glotsos, J.; Bountouroglou, N; Karvounis, N.; Ziras, Nikolaos; Athanassiou, Athanassios

doi:10.1016/s0959-8049(02)00027-8

Cited by 15 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the 3 years which elapsed from then, several studies have been published, which evaluated the activity of this combination in a wide range of solid tumors; however, data concerning its use in BC patients have not been reported yet [18,19,20,21,22,23,24,25]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients

Frasci¹,

D’Aiuto²,

Thomas³

et al. 2005

Oncology

View full text Add to dashboard Cite

Purpose: To evaluate the feasibility and activity of combination treatment with docetaxel (DTX) and irinotecan (CPT-11), given together every other week, combined with filgrastim support, in anthracycline- and paclitaxel-pretreated breast cancer (BC) patients. Patients and Methods: Advanced BC patients pretreated with anthracycline- and paclitaxel-based chemotherapy were eligible. DTX (80 mg/m²) and CPT-11 (100 mg/m²) were given biweekly with filgrastim support (300 µg/day on days 4–7). Results: Fifty patients (48 with metastatic and 2 with locally advanced cancer) were enrolled, with a total of 318 cycles being delivered. Thirty-one patients had visceral localizations. All patients had received epirubicin plus paclitaxel, with or without cisplatin, as front-line treatment for advanced disease. Overall, fatigue and diarrhea were the main chemotherapy-related toxicities in this study, being severe in 10 (20%) and 4 (8%) patients. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 18 (36%) and 6 (12%) patients, respectively. Red blood cell transfusions were required in 4 patients. A total of 32 objective responses were registered (overall response rate, ORR = 64%, 95% confidence interval = 49–77%), including 8 complete responses (16%). An additional 8 patients showed stable disease. After a median follow-up of 18 (range 4–29) months, 30 patients were still alive, and 19 were progression free; median progression-free and overall survivals were 10 and 23 months, respectively. Conclusions: Biweekly DTX/CPT-11 with G-CSF support is a well-tolerated and highly effective approach in anthracycline-/paclitaxel-pretreated patients. The very promising ORR and survival outcome observed in this subset of patients with a poor prognosis suggest that this regimen might play a major role in the management of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…DTX-CPT11, either alone or in combination with carboplatin, were tested in NSCLC patients, showing a very encouraging ORR and survival outcome [18,19,20,21]. This regimen has also been tested in cancers in the upper gastrointestinal tract and pancreatic cancers, showing a definite antitumor activity [22,23,24,25].…”

Section: Discussionmentioning

confidence: 99%

Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients

Frasci¹,

D’Aiuto²,

Thomas³

et al. 2005

Oncology

View full text Add to dashboard Cite

show abstract

“…In another phase II study [26] using the same combination but in a weekly schedule as front line treatment the results were similar to our study with the exception of a somewhat lower response rate and lower incidence of grade 4 neutropenia. In the phase II study by Pectasides et al [27] the addition of carboplatin in the docetaxel/irinotecan combination resulted, as expected, in higher response rate which, however, was associated with a less favorable toxicity profile while the survival could not demonstrate an important improvement.…”

Section: Discussionmentioning

confidence: 61%

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

et al. 2005

View full text Add to dashboard Cite

“…In contrast to the clinical trials reporting lacrimation disorders with weekly administration of docetaxel to women with advanced breast cancer, 15 of 19 phase II-III studies evaluating this treatment of non-small cell lung cancer did not report epiphora or conjunctivitis as a regimen-related adverse event. 17,20,53,54,[83][84][85][86][87][88][89][90][91][92][93] Six of these 15 articles reported only serious (≥ grade 3) adverse events, so excess lacrimation and conjunctivitis may have been excluded because they are generally mild in severity. 54,[83][84][85][86]93 It is possible that epiphora was less frequent in studies infusing weekly docetaxel for the treatment of non-small cell lung cancer because of the administration of a lower cumulative dose relative to the clinical trials using weekly docetaxel for the treatment of metastatic breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel-Associated Epiphora

Kintzel¹,

Michaud

Lange

2006

Pharmacotherapy

View full text Add to dashboard Cite

Docetaxel is a semisynthetic taxane indicated for the treatment of advanced breast, prostate, and non-small cell lung cancers; it is also used for the treatment of various other solid tumors. The standard intermittent dosage of docetaxel is 60-100 mg/m2 every 3 weeks. At this dose and schedule, myelosuppression is common and neutropenia is usually the dose-limiting toxicity. Weekly administration of docetaxel 20-42 mg/m2 is being tested in the treatment of advanced solid tumors in order to improve patient tolerance by reducing the interval dose and to maintain therapeutic efficacy by increasing overall dose intensity. Asthenia and peripheral neuropathy can limit continued administration of weekly docetaxel. Epiphora (excess tearing due to narrowing or blockage of the lacrimal outflow passages) is associated with repeated weekly administration of docetaxel. This adverse effect can interfere with activities of daily life and negatively affect quality of life. Epiphora may be an underreported adverse effect of treatment because of underrecognition by clinicians and patient embarrassment with respect to seemingly uncontrolled tearing. The use of weekly docetaxel administration is expanding; therefore, patients should be educated to recognize and report signs and symptoms of epiphora. It is important for clinicians participating in the care of patients undergoing treatment with docetaxel to monitor for excess tearing and signs of eye irritation to ensure timely management of treatment-related epiphora.

show abstract

Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer

Cited by 15 publications

References 33 publications

Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients

Biweekly Docetaxel-Irinotecan Treatment with Filgrastim Support Is Highly Active in Antracycline-Paclitaxel-Refractory Breast Cancer Patients

Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study

Docetaxel-Associated Epiphora

Contact Info

Product

Resources

About